LaViscount, operator. call. of Officer and our XXXX everyone Welcome Mark Medical's Helius Chief earnings Operating you Officer; I'm first Vice Manager this conference on General and President and quarter Joyce Chief Thank joined Leno, our Financial to by operations. Canadian evening
of focus discussion our and we commercialization. Let to I'll are quick progress you we are create shareholder brief remarks agenda a begin of United the in as part our we initiatives focused as value. my to prepare me with with continued Helius on today to a what going on for reposition provide States strategy on
progress balance with enhance on thoughts have Following briefly and Canada. recent and our Joyce results, made expectations. discussion, review financial capital an will to condition additional our our will this we provide commercial share Mark the our you discuss then on secure update activities in sheet first some quarter
for an in our get before we progress initiatives U.S. on closing questions. on call near-term outlook XXXX share recent in and some will I the let's update longer-term started With that, remarks, thoughts Joyce's Following with open our
achievement U.S. made in announced unmet U.S. device. our sclerosis obtaining quarter of March on our first first very regulatory the for shift XXXX, regulatory indication MS strategy and tirelessly X shareholders clearance and bringing our patient prepare quarter clinical look MS. During worked remains of bring our of progress gait committed this we commercializing marketing to team to validation U.S. to and PoNS the and our regulatory due for innovative million it personally for of Since and our first and device efficacy of is represents moderate the population it of for in receipt the safety to and are we accordingly. effectively. PoNS significant to employees, we to and that our XXXX. an history during high for to PoNS or multiple were to make our first we to Approximately U.S. Medical as strategy the milestone treatment clinical suffering one approximately This people congratulate Helius the pathway our the who the an in symptoms pursue the device strong helping XXXX we clearance in to technology our research of To U.S. short to important U.S. U.S. a possible. patients authorization secure like forward the our from quickly U.S. for deficit The would the medical needs MS. this technology in in later, of conducted year continually And to proud term from mild secure most clearance I participated end, Helius be PoNS
activities groundwork four the to following Specifically, we in our lay for part are currently initiatives focused pre-commercial successful U.S. commercialization. XXXX as of on the
securing to First, our across and distribute device required the accreditation the U.S. licensing PoNS
and execute lead processes to U.S. efforts. team to dedicated our a initial commercialization building Second,
PoNS Third, medical and refining clients engage strategic pursuing our adopters for in educate fourth, target, potential early coverage treatment.
these more to secure efforts four discuss accreditation. licensing minute a detail, beginning take each me and our to of with in initiatives Let
each has enable we've already state been months sell licenses report initial XXXX, us the distribute the our with will distribute PoNS secured licenses to team states. we XX product to I'm in our that that device. to will pleased required to-date During of be in working our and to secure able
continue to We expand in to licenses of the U.S. additional market. coverage XXXX pursue our state will
a terms to In our U.S. our team a dedicated and of success. future core of area focus a key second initiative, establishing focus component is ensure
LivaNova United importantly, of and team proven experience, lead last products we and companies. years service topics the Perkins marketing year, of and currently who forward we States. the advising on to commercialization contributions addition for medical commercialization. her of with director University classified expand Cancer expanded appointed at she a board brings our we over to prepare look will to future spent in in personnel More new who leadership addition companies as durable On already their marketing support Center, directors a and be of subsidiaries the Sherrie XXXX, healthcare key commercial to Perkins, mentoring nearly are our with equipment. and our strategy appointment efforts. early our sales working enhance the venture has expertise establishing to our Ms. with MD operations significant significant commercial team we of with activities. team the Texas, operations, where and working be guidance instrumental and medical related of valuable to She a its our provides as on of as serves March joins XX, experience including neuromodulation we she XX for commercializing and and stage a our years In Late XX technologies Anderson member
on execution awareness and the its U.S. raise and treatment our facilitate of process to focus PoNS also of U.S., adoption. building In the commercial two efforts of will are model We in for our audiences. processes strategy our primary the
the awareness by physicians in potential First, we of practice. how who will patients educated treated of PoNS prescribers And we our on will believe intend our we on the key neuro-rehabilitation and neurologists employ personnel serve their we second, be will believe them to raising focus other at in and key now neurology educating can treatment engage device. where centers, community they PoNS as
to our two on potential We that demand focused select relationships we our the have to of engaging with centers be primary initiative, greatest technology. early of neurologists are our create by order development to audiences. establishing processes neuro-rehab these and respect in targeted to third our plan prioritize With team adopters and
multiple our our the our them tasked to those PoNS team with deficit. board sales in and and formed reimbursement being adopters and of U.S. their scientific first benefits late gait education, During addressing To initial MS commercialization, engaging educating refine our patients market sclerosis overall advisory approach needs XXXX. the will inform with commercialization strategy engagement potential unmet we a adopt be and with to our treatment, on early access innovative of
medical doctors a in board scientific neuro-rehab work prominent Our body of clinicians researchers, consists advisory from MS with and medical U.S. and of institutions.
and to initial as Our our leveraging insight and their look prepare productive scientific we strategy forward work been expertise to for with has we advisory board our refine commercialization.
coverage of Turning to our under expected of and majority customers final PoNS widespread The for pursuing pending are U.S. our our fourth reimbursement the initiative, initial Medicare. the receipt coverage. pay treatment cash
have device. or coverage Medicare focus earnings call, goal on coverage mind, been the rules. have technology Medicare we this closely our of the is pursuing on initial of With discussed monitoring development we innovative prior MCIT for in PoNS our As
last FDA breakthrough date quickly additional delayed to to to an a January U.S. Friday, determine four XX, will achieved the designated medical CMS March market were window. receive that CMS we were announced devices the XX next As authorization Medicare period that for comment to steps. MCIT this final years market delayed pleased XX rule past XX, CMS authorization. reminder, XXXX pathway effective CMS coverage December provided rule. from represents nationwide On of effective appropriate until finalizing an opportunity On of and for for the a they new see this the of the date This provide was during date days year,
by Helius While is pleased obviously pathway has this we to delay, that the withdrawn. not see disappointed been were
As announcement implications. we its recent the evaluate and
our Medicare. We to under coverage strategy multi obtain to pursue are PoNS continuing
potential device Stepping its back, to coverage continue MCIT With continue first development. in will tailwind therapists monitor a process of U.S. patients and the U.S. of for initial end PoNS, and this securing, indication the performance constituents culminated awareness receipt CMS by approximately provide device we with opportunity community, all Leno which on of execution in in in important enrolled in with authorized pathway to beyond. in FDA strategic to requirements MCIT U.S. dedicated million at team first expectations. over to the and our forward efforts review now authorization important treat consistent regulatory laying in with year as Medicare, an of to XX patients activities the through awareness for year we work in ultimate among revenue We MS clearance update look Specifically, to market the progress view this commercial are Mark? you U.S. MS its our Mark closely implementing commercialization hand, to are of Canada. only adoption since MS administrators, Americans engage regardless of our on a neurologists, pursue by as will from excited to raising our the pursuing and our our quarter continue and PoNS to last outcome to including first we our of deficit treatment. an to gait we'll physical effective we XXXX new With build an obtain support and our authorization marketing as began rule. the we focused clarify the the groundwork now highly coverage, quarter, the and first we establishing and
